KemPharm

Drug Development for Rare Diseases is Littered with Regulatory Roadblocks
BioSpace
Fri, 08/19/22 - 10:41 am
Rare Diseases
drug development
regulatory
KemPharm
Orphazyme
Orphazyme agrees to sell itself, and its 'pipeline-in-a-product,' to KemPharm
Endpoints
Mon, 05/16/22 - 10:20 am
Orphazyme
KemPharm
M&A
arimoclomol
KemPharm Snags Approval for ADHD Prodrug
BioSpace
Thu, 03/4/21 - 11:25 pm
KemPharm
ADHD
prodrugs
FDA
Azstarys
Approved! FDA Grants IND Clearance to Three More Candidates Today
BioSpace
Thu, 01/28/21 - 11:14 pm
FDA
IND clearance
COPD
Zofin
Organicell
COVID-19
Passage Bio
PBFT02
frontotemporal dementia
KemPharm
KP879
stimulant use disorder
KemPharm shoots for ADHD filling in 2019
Biopharma Dive
Mon, 07/9/18 - 07:02 pm
KemPharm
ADHD
KP415
clinical trials
FDA overrides adcomm, shoots down KemPharm’s opioid
Fierce Biotech
Mon, 06/13/16 - 11:29 pm
FDA
advisory panels
KemPharm
Apadaz
opioids
painkillers
2 FDA Decisions To Watch In June
Seeking Alpha
Wed, 06/1/16 - 10:54 am
FDA
rociletinib
Clovis Oncology
KemPharm
Apadaz
Revenues From Opioids Drying Up For Pharmaceuticals
Seeking Alpha
Thu, 05/26/16 - 09:46 am
opioids
painkillers
KemPharm
Pfizer
Teva Pharmaceuticals